EANS-Adhoc: LifeWatch AG / Announces `NiteWatch´ Home Sleep Apnea Testing Service

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products

28.07.2009

Neuhausen am Rheinfall / Switzerland and Chicago / USA, July
28, 2009 - LifeWatch AG's (SIX Swiss Exchange: LIFE) American
subsidiary LifeWatch Services, Inc., the leading provider of
wireless telemedicine services in the U.S., is set to expand into
the promising sleep apnea home sleep testing market.

LifeWatch, the leading U.S. provider of wireless telemedicine
services, announces the expansion of its current remote medical
monitoring services with a sleep apnea home sleep testing service.
NiteWatch which will be launched during Q4 2009 to specific
customers, with an expanded roll-out planned in 2010.

Sleep Apnea, which is characterized by the temporary suspension of
breathing during sleep for as much as 100 times a night, affects
approximately 38 million individuals in the U.S. Sleep apnea is
associated with an increased risk of cardiovascular disease,
stroke, high blood pressure, arrhythmias, diabetes, and serious
accidents due to fatigue and sleepiness. Patients with untreated
sleep apnea have shown to incur double the healthcare costs of those
that have been diagnosed and treated. Despite its high
prevalence and associated complications, less than 1 in 7
patients who suffer from sleep apnea in the U.S. have been
diagnosed.

Failure to diagnose sleep apnea is in part due to the fact that a
patient is required to sleep in a strange and uncomfortable
environment at a sleep lab or clinic, while wearing an apparatus
that makes the act of sleeping almost impossible. Patients are
further discouraged by the fact that sleep clinic rooms often
book out months in advance due to the increased demand.
Alternatively, home sleep testing (HST) solutions are emerging
as the appropriate diagnostic solution for more than 95% of sleep
apnea cases, as they can be performed in the comfort of one's normal
sleeping environment. In early 2009, Medicare issued a coverage
decision memo specific to HST for sleep apnea diagnosis after an
extensive review of clinical studies conducted to validate the
utilization of home sleep testing (HST). The decision declared that
the use of home sleep testing technologies demonstrates improved
health outcomes in Medicare beneficiaries who have sleep apnea
and received the appropriate treatment, and that these tests are
thus reasonable and necessary.

"The introduction of home sleep testing will greatly improve the
quality of life of the many patients who are reluctant to go to a
sleep lab", stated Alan Kadish, M.D. "By offering services in the
comfort of their home, these patients are almost certain of
receiving a correct diagnosis which can be treated
appropriately," he added. Dr. Kadish is a member of
LifeWatch's Medical Advisory Board is a fellow of both the American
College of Cardiology and the American Heart Association and Senior
Associate Chief of Cardiology at Northwestern Memorial Hospital.

Dr. Yacov Geva, Chairman and CEO of LifeWatch AG, stated, "We are
excited to announce our first steps into the promising home sleep
testing market, and are confident that our NiteWatch service will
contribute to a patient's improved quality of life through
earlier and more accurate detection that allows for more
appropriate treatment options".

About LifeWatch AG

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless cardiac monitoring services. LifeWatch services
treat high-risk and chronically ill patients, health conscious
consumers and wellness programs. LifeWatch has subsidiaries in the
United States, the Netherlands, Japan, the United Kingdom,
Switzerland and Israel. LifeWatch AG is the parent company of
LifeWatch Services Inc., a leading US-based cardiac monitoring
service provider, and manufacturer of telecardiology products.
www.lifewatch.com

Sign-up for customized e-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these forward
looking statements largely on current expectations and projections
about future events and financial trends that it believes may affect
the financial condition, results of operations, business strategy,
short term and long term business operations and objectives, and
financial needs. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions. In light of these
risks, uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based
only on data available to LifeWatch AG at the time of the issue of
this press release. LifeWatch AG does not undertake any obligation to
update any forward-looking statements contained in this press release
as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

-----------------------

Press Release

July 28, 2009

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: LifeWatch AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG

Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com

Europe

Sensus Investor and Public Relations GmbH, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch

USA

Westwicke Partners

E-mail asher.dewhurst@westwicke.com

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / free trade